A

    APLS (APLS)

    Official site

    BIOTECHNOLOGY

    $41.03
    +0.00 (+0.00%)

    Last updated: May 14, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    31%(11/35)
    Avg Surprise
    -6.61%
    Streak
    1 Q

    Upcoming Estimates

    Jun 30, 2026
    EPS Consensus$-0.32
    Range$-0.49 - $-0.16
    8 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate Drift
    90d ago$-0.35-11.1%
    60d ago$-0.31+2.5%
    30d ago$-0.33-3.7%
    7d ago$-0.33-3.7%
    Current$-0.32
    Revenue Consensus
    $210M
    Range$201M - $215M
    9 analysts
    Sep 30, 2026
    EPS Consensus$-0.28
    Range$-0.60 - $-0.10
    8 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate Drift
    90d ago$-0.33-17.0%
    60d ago$-0.24+12.7%
    30d ago$-0.26+5.9%
    7d ago$-0.26+5.9%
    Current$-0.28
    Revenue Consensus
    $219M
    Range$207M - $234M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.21---
    Sep 26EST
    		-$-0.28---
    Jun 26EST
    		-$-0.32---
    Mar 26
    		$0.15N/A+133.73%Beat+120.3%
    Dec 25
    		$-0.47$-0.38-24.01%Miss-62.1%
    Sep 25
    		$1.67$1.55+7.74%Beat+461.2%
    Jun 25
    		$-0.33$-0.48+31.25%Beat-17.9%
    Mar 25
    		$-0.74$-0.54-37.04%Miss-76.2%
    Dec 24
    		$-0.29$-0.40+27.84%Beat+60.3%
    Sep 24
    		$-0.46$-0.30-54.13%Miss+60.5%
    Jun 24
    		$-0.28$-0.32+12.50%Beat+72.5%
    Mar 24
    		$-0.42$-0.47+10.64%Beat+73.1%
    Dec 23
    		$-0.73$-0.69-5.80%Miss+51.3%
    Sep 23
    		$-1.17$-0.86-36.05%Miss+33.1%
    Jun 23
    		$-1.02$-1.32+22.73%Beat+30.1%
    Mar 23
    		$-1.56$-1.46-6.85%Miss-9.9%
    Dec 22
    		$-1.50$-1.57+4.46%Beat+6.8%
    Sep 22
    		$-1.75$-1.45-20.69%Miss+23.2%
    Jun 22
    		$-1.46$-1.36-7.35%Miss+46.3%
    Mar 22
    		$-1.42$-1.32-7.58%Miss+38.8%
    Dec 21
    		$-1.61$-1.54-4.55%Miss-273.1%
    Sep 21
    		$-2.28$-1.70-34.12%Miss-27.4%
    Jun 21
    		$-2.72$-1.69-60.95%Miss-73.2%
    Mar 21
    		$-2.32$-1.62-43.21%Miss-1.3%
    Dec 20
    		$0.93$-0.75+224.00%Beat+152.5%
    Sep 20
    		$-1.79$-1.58-13.29%Miss-62.7%
    Jun 20
    		$-1.57$-1.34-17.16%Miss-40.2%
    Mar 20
    		$-2.29$-1.38-65.94%Miss-163.2%
    Dec 19
    		$-1.77$-1.14-55.26%Miss-172.3%
    Sep 19
    		$-1.10$-1.01-8.91%Miss-71.9%
    Jun 19
    		$-1.12$-0.77-45.45%Miss-83.6%
    Mar 19
    		$-0.87$-0.67-29.85%Miss-102.3%
    Dec 18
    		$-0.65$-0.70+7.14%Beat-8.3%
    Sep 18
    		$-0.64$-0.69+7.25%Beat+53.3%
    Jun 18
    		$-0.61$-0.47-29.79%Miss+51.6%
    Mar 18
    		$-0.43$-0.33-30.30%Miss+59.8%
    Dec 17
    		$-0.60$-0.48-25.00%Miss-
    Sep 17
    		$-1.37$-0.87-57.47%Miss-
    Jun 17
    		$-1.26$0.00N/AMiss-
    Mar 17
    		$-1.07$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$41.02
    SMA 20$40.98
    SMA 50$32.78
    SMA 200$25.97
    EMA 10$40.98
    EMA 20$40.06
    EMA 50$35.17
    EMA 200$27.28

    MACD

    Line: 1.81Signal: 2.43Hist: -0.62

    ADX

    ADX: 73.0+DI: 62.6-DI: 8.2

    Aroon & PSAR

    Aroon Up76.0
    Aroon DownN/A
    PSAR$40.99

    Bollinger Bands

    Upper Band$41.09
    Lower Band$40.87
    %B Position55%(Middle)
    Band Width0.72

    RSI (14-Day)

    Overbought
    84.5

    Momentum Oscillators

    Stoch %K58.9
    Stoch %D60.2
    Williams %R-47.8
    ROC (10d)0.2%
    Momentum0.08
    CCI (20d)81.0
    MFI (14d)33.3

    Volatility Measures

    ATR (14d)$0.31(0.7%)
    StdDev (20d)0.06
    Hist Vol1.9%(Low)

    Volume Flow

    VWAP$41.03
    OBV46.0M
    AD Line-138.2M
    CMF (20d)-0.374

    Volume Metrics

    Avg Vol (20d)7.2M
    Vol RatioN/A
    VWMA (20d)$41.01

    Pivot Points

    R3$41.10
    R2$41.08
    R1$41.06
    Pivot Point$41.04
    S1$41.02
    S2$41.00
    S3$40.98

    Advanced Oscillators

    TSI72.71
    Ultimate Osc55.7
    KST453.69

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$268.30M$199.91M$458.58M$178.49M$166.80M$212.53M$196.83M$199.69M$172.32M$146.38M$110.40M$94.97M
    Cost of Revenue$0$29.72M$0$0$0$40.86M$0$0$0$19.91M$0$0
    Gross Profit$268.30M$199.91M$458.58M$178.49M$166.80M$212.53M$196.83M$199.69M$172.32M$146.38M$110.40M$94.97M
    Operating Expenses$241.83M$251.06M$235.40M$211.78M$250.13M$238.69M$244.11M$229.13M$234.41M$230.89M$247.48M$215.41M
    R&D$76.96M$74.23M$68.19M$67.02M$86.42M$76.35M$88.57M$77.95M$84.70M$69.28M$79.42M$95.66M
    SG&A$124.32M$147.10M$142.68M$131.14M$129.34M$121.48M$121.98M$128.08M$129.50M$141.70M$145.65M$111.37M
    Operating Income$26.47M$-51,142,000$223.18M$-33,286,000$-83,328,000$-26,166,000$-47,280,000$-29,443,000$-62,090,000$-84,517,000$-137,080,000$-120,441,000
    Interest Income$2.91M$3.50M$4.38M$2.61M$2.66M$3.40M$2.89M$3.18M$3.30M$4.55M$4.99M$6.00M
    Interest Expense$10.32M$10.85M$11.28M$11.15M$11.05M$11.53M$12.53M$9.36M$6.97M$7.40M$7.31M$7.34M
    Income Before Tax$19.15M$-58,638,000$216.32M$-41,685,000$-91,884,000$-36,067,000$-56,853,000$-37,543,000$-66,253,000$-87,153,000$-140,004,000$-121,843,000
    Income Tax Expense$496,000$313,000$602,000$466,000$341,000$286,000$592,000$114,000$170,000$1.42M$233,000$194,000
    Net Income$18.66M$-58,951,000$215.72M$-42,151,000$-92,225,000$-36,353,000$-57,445,000$-37,657,000$-66,423,000$-88,576,000$-140,237,000$-122,037,000
    EBITDA$27.51M$-50,311,000$224.19M$-32,080,000$-82,456,000$-26,897,000$-46,095,000$-30,681,000$-62,069,000$-83,750,000$-137,146,000$-119,932,000
    EBIT$26.55M$-51,293,000$223.22M$-33,140,000$-83,493,000$-27,931,000$-47,210,000$-31,368,000$-62,589,000$-84,301,000$-137,683,000$-120,504,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about APLS

    News

    Biogen beats quarterly estimates as newer drugs drive growth

    Biogen exceeded Wall Street's expectations for its second-quarter profit and revenue, driven by strong growth in its rare-disease medications despite a decline in sales of its older multiple sclerosis drugs. The company raised its full-year revenue forecast to a mid-single-digit percentage growth, a significant improvement from its previous forecast of a decline. This positive performance is attributed to recent acquisitions and newer products like the Alzheimer's drug Leqembi, alongside an optimistic pipeline.

    WTVB•7/29/26•
    Somewhat-Bullish

    Apellis Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

    Apellis Pharmaceuticals had approximately 635 employees worldwide as of March 2026, representing a 2.3% year-over-year increase but a 13.4% decline from 2023. The company, headquartered in Waltham, Massachusetts, is actively hiring despite a 64.2% decrease in active job postings from 2025 to 2026. Most of its workforce is concentrated in the United States, and the average employee salary is $198,566.

    Revelio Labs•7/28/26•
    Neutral

    Price to earnings forward of Apellis Pharmaceuticals, Inc. – LS:A2JAAW

    This page provides financial information for Apellis Pharmaceuticals, Inc. (LS:A2JAAW), specifically focusing on its price-to-earnings forward metric. The data is provided by ICE Data Services and FactSet, with SEC filings by Quartr. It appears to be a stub or placeholder page without detailed financial figures.

    TradingView•6/28/26•
    Neutral

    Apellis Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Sullivan Timothy Eugene

    This document is a statement of changes in beneficial ownership of securities for Timothy Eugene Sullivan, an officer at Apellis Pharmaceuticals. It indicates a filing under Form 4, which is used to report changes in ownership of company stock by insiders.

    Moomoo•6/20/26•
    Neutral

    Apellis Pharmaceuticals Inc (APLS) Earnings Forecast: Future EPS & Revenue Growth Estimates

    Apellis Pharmaceuticals Inc (APLS) has an earnings forecast score of 6.48, ranking 132 out of 156 in the Pharmaceuticals industry as of May 13, 2026. Analysts project a price target of USD 36.00, with a high of USD 55.00 and a low of USD 19.00. The company's previous quarter's EPS was USD -0.47, significantly below the market expectation of USD 0.15, while the next quarter is expected at USD -0.33.

    TradingKey•6/18/26•
    Neutral

    Frequently Asked Questions About APLS

    Does APLS pay dividends?
    APLS (APLS) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In